Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Transfusion Dependent Thalassemia”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)WithdrawnNCT02069886
What this trial is testing

Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia

Who this might be right for
Thalassemia (Transfusion Delendent)
Novartis Pharmaceuticals
Not applicableLooking for participantsNCT05776173
What this trial is testing

Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia

Who this might be right for
β-thalassemia Major
Shanghai BDgene Co., Ltd. 10
Testing effectiveness (Phase 2)Study completedNCT02151526
What this trial is testing

A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease

Who this might be right for
Beta-Thalassemia MajorSickle Cell Disease
Genetix Biotherapeutics Inc. 7
Not applicableUnknownNCT06164821
What this trial is testing

Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia

Who this might be right for
Effect of Drug
Hematology department of the 920th hospital 10
Large-scale testing (Phase 3)Study completedNCT00176852
What this trial is testing

Stem Cell Transplant for Hemoglobinopathy

Who this might be right for
Sickle Cell DiseaseThalassemiaSevere Congenital Neutropenia+2 more
Masonic Cancer Center, University of Minnesota 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT06308159
What this trial is testing

An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia

Who this might be right for
Beta-Thalassemia
Lantu Biopharma 6
Testing effectiveness (Phase 2)Study completedNCT01740713
What this trial is testing

Pharmacokinetic Study of Deferiprone in Paediatric Patients

Who this might be right for
Chronic Iron Overload
Consorzio per Valutazioni Biologiche e Farmacologiche 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT05577312
What this trial is testing

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Who this might be right for
Beta-Thalassemia
Bioray Laboratories 39
Testing effectiveness (Phase 2)Looking for participantsNCT06280378
What this trial is testing

Β-Thalassemia Treatment with KL003 Cell Injection

Who this might be right for
Transfusion-dependent Beta-Thalassemia
Kanglin Biotechnology (Hangzhou) Co., Ltd. 41
Testing effectiveness (Phase 2)Study completedNCT04987489
What this trial is testing

Etavopivat in Patients With Thalassemia or Sickle Cell Disease

Who this might be right for
Sickle Cell DiseaseThalassemia
Forma Therapeutics, Inc. 53
Testing effectiveness (Phase 2)Study completedNCT05355766
What this trial is testing

Long-term Clinical Study of CN128 in Thalassemia With Sever Liver Iron Overloaded Patients

Who this might be right for
ThalassemiaIron Overload
Hangzhou Zede Pharma-Tech Co., Ltd. 16
Not applicableNot Yet RecruitingNCT07480980
What this trial is testing

Evaluation of Micro RNA-155 Expression in Relation to Alloantibody Formation in Transfusion-Dependent Patients

Who this might be right for
Red Cell AlloantibodiesBlood Transfusion-DependentBeta Thalassemia
Assiut University 100
Testing effectiveness (Phase 2)WithdrawnNCT01948817
What this trial is testing

Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses

Who this might be right for
Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)UnknownNCT02453477
What this trial is testing

Gene Therapy for Transfusion Dependent Beta-thalassemia

Who this might be right for
Beta-Thalassemia
IRCCS San Raffaele 10
Testing effectiveness (Phase 2)Study completedNCT00901199
What this trial is testing

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Who this might be right for
ThalassemiaIron Overload
Elliott Vichinsky 22
Large-scale testing (Phase 3)Study completedNCT03651102
What this trial is testing

Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

Who this might be right for
Thalassemia
Blood Diseases Clinic 654
Not applicableEnded earlyNCT02179359
What this trial is testing

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Who this might be right for
Sickle Cell DiseaseTransfusion Dependent Alpha- or Beta- ThalassemiaDiamond Blackfan Anemia+5 more
Masonic Cancer Center, University of Minnesota 38
Not applicableUnknownNCT06041620
What this trial is testing

Safety and Efficacy Evaluation of Autologous CRISPR-Cas12b Edited Hematopoietic Stem Cells

Who this might be right for
Thalassemia, BetaThalassemia Major
Institute of Hematology & Blood Diseases Hospital, China 2
Large-scale testing (Phase 3)Study completedNCT07210450
What this trial is testing

Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia

Who this might be right for
Pulmonary Artery PressureThalassemiaNon-transfusion Dependent Thalassemia
Mazandaran University of Medical Sciences 8
Testing effectiveness (Phase 2)Ended earlyNCT01459718
What this trial is testing

Safety and Efficacy of Deferasirox in Combination With Desferoxamine in β-thalassaemia Patients With Severe Cardiac Iron Overload

Who this might be right for
Transfusion-dependent β-thalassemia PatientsCardiac Iron Overload
Novartis Pharmaceuticals 32
Next Page